Analysis of clinical evidence for traditional Chinese medicines to treat corona virus disease 2019
Objective:To evaluate the efficacy and safety of 18 traditional Chinese medicines (TCMs) in the prevention and treatment of corona virus disease 2019 (COVID-19), in order to provide scientific evidence and guidance for clinical practitioners.Methods:All the clinical studies related to TCM treatment of COVID-19 published as of March 16, 2023 were retrieved in six Chinese and English literature databases: PubMed, Embase, Cochrane Library, CNKI, Wanfang Data, and VIP Database. The basic characteristics, sample size, intervention measures, and main outcomes of studies on 18 TCMs were compared and analyzed, and the GRADE approach was used to assess the quality of evidence.Results:Qingfei Paidu decoction, Lianhua Qingwen capsules (granules), Xuebijing injection, Shufeng Jiedu capsules, and other TCMs could effectively relieve the fever, cough, fatigue, and other symptoms of COVID-19 patients, shorten the hospitalization time and time to negative conversion of nucleic acid test result, increase the cure rate and recovery rate, reduce the rates of deterioration and mortality, improve pulmonary imaging manifestations, reduce inflammation level, and improve blood biochemical indicators and immune function indicators of the patients.Conclusion:The 18 TCMs identified have obvious therapeutic effects and good safety for COVID-19.
万方数据
